Notoginsenoside Fe  (Synonyms: Notoginseng triterpenes; Ginsenoside Mb)

Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma^[1][2][3].

Notoginsenoside Fe (50 μM; 24 h) significantly reduces cell viability of human neuroblastoma SH-SY5Y cells, with a weaker inhibitory effect than notoginsenoside Ft1 (HY-N0910)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Notoginsenoside Fe (10 mg/kg; i.p.; daily; 14 days) reduces diet-induced obesity in male C57BL/6 mice by decreasing body weight by 12%, reducing food intake, improving glucose tolerance, ameliorating hepatic steatosis, reducing fat mass, increasing energy expenditure, and inhibiting lipogenesis gene expression^[1].
Notoginsenoside Fe (5 mM in 2 μl per mouse; i.c.v.; single dose) reduces food intake in diet-induced obese male C57BL/6 mice and specifically activates paraventricular nucleus neurons^[1].
Notoginsenoside Fe (10 mg/kg; i.p.; daily; 6 days) has no effect on body weight, food intake, or hypothalamic neuron activation in healthy lean male C57BL/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

917.13

C₄₇H₈₀O₁₇

88105-29-7

Solid

Light yellow to yellow

C[C@]12[C@@](C)([C@]3([H])C[C@@H](O)[C@]1([H])[C@@]([H])([C@](C)(CC/C=C(C)/C)O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](CO)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)CC2)CC[C@@]([C@]3(C)CC6)([H])C(C)(C)[C@H]6O[C@@]7([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Li H, et al. Notoginsenoside Fe suppresses diet induced obesity and activates paraventricular hypothalamic neurons. RSC Adv. 2019;9(3):1290-1298. Published 2019 Jan 11.

  [2]. Guo X, et al. Protective effects of Notoginsenoside R2 on reducing lipid accumulation and mitochondrial dysfunction in diabetic nephropathy through regulation of c-Src. Chin Med. 2025;20(1):10. Published 2025 Jan 15.

  [3]. Gao B, et al. p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft1 on human neuroblastoma SH-SY5Y cells. Life Sci. 2014;108(2):63-70.  [Content Brief]